Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nycomed MRI liver imaging agent under review at FDA.

This article was originally published in The Gray Sheet

Executive Summary

NYCOMED S-095 MRI LIVER IMAGING AGENT PENDING AT FDA, Hafslund Nycomed Exec VP-R&D Trond Jacobsen said Nov. 8 at an Oppenheimer and Co. health care conference in New York City. A new drug application for the liver specific magnetic resonance imaging agent "was filed some weeks ago," Jacobsen reported. The agent allows study of "very small metastases or local lesion tumors in the liver."
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT005078

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel